300683.SZ
海特生物
SZSE · Healthcare · C 制造业 · CN
CNY 25.78
−11.41%Year over year
Reported trailing growth
- Revenue
- -19.3%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -3.0%
- Operating cash flow
- +19.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026